![]() | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral.(January 2016) |
Company type | Public |
---|---|
Traded as | Nasdaq: PHIO |
Industry | Biotechnology |
Founded | 2011 |
Headquarters | Marlborough, Ma. |
Key people | Robert Bitterman (president and CEO) |
Website | www |
Phio Pharmaceuticals Inc. is a US biotechnology company focused on the field of siRNA. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.[1]